Clinical trial
A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects
NCT00973388 is registered in ClinicalTrials.gov with Tibotec BVBA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects
- Lead sponsor
- Tibotec BVBA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- January 31, 2010
- Enrollment
- 44 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.